Retinalgenix Technologies INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
RetinalGenix Technologies Inc. announced the resignation of its independent auditor, Liebman Hymowitz, LLP, effective July 13, 2026, and the appointment of Vilki & Co. as its new auditor.
OID
RetinalGenix Technologies Inc. announced the immediate resignation of its Chief Financial Officer, Michael Cory Zwerling, effective March 22, 2026.
OID
RetinalGenix Technologies Inc. has amended its warrant agreement with Sanovas Ophthalmology, LLC, restricting the exercise of warrants until at least February 1, 2030, or three years after a potential uplisting to Nasdaq or NYSE American.
OID
A Delaware court order has voided 3 million shares of RetinalGenix Technologies Inc.'s Series F Preferred Stock previously issued to Halo Management LLC.